The 2022 performance of the chain pharmacy giant will usher in an upward turning point!

With the advancement of policies such as prescription outflow, public hospital reform, medical insurance fee control, volume-based procurement, and "dual-channel" policies, the domestic pharmaceutical retail industry has undergone tremendous changes in recent years
.
Among them, large chain pharmacies continue to build and merge with the help of capital to further expand the chain, while more and more small and medium-sized pharmacies are beginning to be eliminated or merged at an accelerated rate, resulting in a continuous increase in the concentration of the entire industry
.
From the perspective of the industry, under the continuous change of policies, the chain pharmacy giants are expected to undertake sustained high performance in the future, and the upward trend of performance will become more and more obvious
.
Compared with single drugstores, chain drugstore giants have many years of high-standard store construction and operation experience, and have a sound management system, strict quality control and drug storage and logistics system, and have a strong ability to undertake outflow of prescriptions
.
In this regard, the industry expects that the upward trend of these chain drugstore giants' performance in 2022 will become more and more clear
.
In fact, out of optimism about the market prospects, large pharmaceutical retail chain companies are constantly increasing the chain rate to occupy the market by "staking the field"
.
It is reported that since last year, many pharmacy giants have launched the "10,000-store plan".
For example, Sinopharm Holding Guoda Pharmacy revealed at a meeting some time ago that by 2025, Guoda Pharmacy will achieve sales of 60 billion and the number of stores.
more than 20,000
.
The People's Pharmacy revealed at the 2020 shareholders' meeting that in the next two years, the people will still maintain the rhythm of rapid store opening, in order to drive the company's future performance to grow steadily
.
According to the three-year plan proposed by the common people in 2019, 2,000 new stores will be added every year until 2022
.
And Jointown also stated at the 2020 annual general meeting that the company will continue to strengthen the layout of its pharmaceutical retail network, attract more individual pharmacies and small and medium-sized chains through the 10,000-store alliance model, and plans to add 30,000 pharmacies within three years
.
In addition, Yifeng Pharmacy also clearly stated at the 2020 annual general meeting held earlier that "the company plans to enter one new province in the past two years, two new provinces in three years, and the annual rate of new store openings is greater than or equal to 2,000..
From the current point of view, the number of major listed pharmacies such as Dashenlin, Yifeng Pharmacy, Common People, Yixintang, and Jianzhijia have reached 1590/1255/1770/1151/557 in the first three quarters of 2021, respectively.
Both have exceeded the number in 2020, and the expansion of leading pharmacies has accelerated significantly
.
In general, under the pressure of stricter regulatory policies and the purchase of drugs in bulk, chain pharmacies are actively adopting expansion models in order to improve their competitiveness.
In this regard, the industry predicts that with the continuous expansion
of chain pharmacy giants, the industry concentration will continue to increase steadily in the future, and the outflow of prescriptions is expected to accelerate under the resonance of multiple factors.
The long-term development space of the industry will be very broad, and industry leaders are expected to Further expand the development advantages
.
At the same time, in 2022, the upward trend of the inflection point of the performance of a large number of pharmacies will become more and more clear, and it is expected to usher in a valuation repair
.
Disclaimer: In any case, the information or opinions expressed in this article, Neither constitutes investment advice to anyone
.